Catch up on coverage from the third day of the 2024 American Academy of Dermatology Annual Meeting.

Shawn Kwatra, MD, presented late-breaking data at AAD 2024 on the largest prurigo nodularis and nemolizumab clinical trial, OLYMPIA.

In an exclusive interview with Gary Dudzik, he shared top 5 considerations dermatology clinicians should have when choosing financial services for their practices and overall financial goals.

Melinda Gooderham, MSc, MD, FRCPC, provided insights into the significance of the DELTA 3 extension data presented at AAD 2024.

Burnett recently spoke with Dermatology Times to discuss the background, methods, and findings of the late-breaking INTEGUMENT-PED data, as well as its potential real-world and clinical implications.

Lloyd Miller, MD, PhD, delves into the new data demonstrating high rates of skin clearance over 52 weeks in adults with moderate to severe plaque psoriasis.

Eichenfield discusses the late-breaking data on roflumilast cream 0.05% in the pediatric patient population and its implications.

Joseph Zabinski, PhD, MEM, of OM1, shares insights at AAD into how artificial intelligence can mature and be a positive tool for disease detection.

Maria Aleshin, MD, FAAD, presented surgical procedures for HS that can be performed in the office.

The congenital ichthyosis session the 2024 AAD Annual Meeting covered real-world patient cases and treatments on the horizon.

Discover the science behind cosmeceutical advancements and the importance of staying informed for enhanced patient care with Zoe Diana Draelos, MD.

The phase 3 studies, BE HEARD I and BE HEARD II, showed significant improvements in skin pain over the 48-week period.

In addition to recapping key highlights from his session, Friedman discusses what is new or upcoming in dermatology that most excites him.

Catch up on coverage from the second day of the 2024 American Academy of Dermatology Annual Meeting.

The international observational study aims to understand how moderate to severe AD affects children under 12 years of age, particularly in terms of height, weight, and BMI.

Alexandra Kimball, MD, FAAD, reviews late-breaking data at AAD on lutikizumab for hidradenitis suppurativa.

Dermatologists are able to connect pediatric patients to psychology clinicians for multidisciplinary care under one roof.

In an AAD late-breaking research session, Joel Gelfand, MD, MSCE, FAAD, presented in-depth results of the LITE Study.

Iltefat Hamzavi, MD, reviews late-breaking data at AAD on upadacitinib as monotherapy.

The American Acne and Rosacea Society welcomed Del Rosso as its new president and he shared key takeaways from his AAD sessions.